Agora Inactive 10-Q10 Feb 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Dec. 27, 2013	Feb. 03, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	27-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'API	'
Entity Registrant Name	'ADVANCED PHOTONIX INC	'
Entity Central Index Key	'0000869986	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	31,240,740

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 27, 2013	Mar. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$116,000	$619,000
Receivables, net	5,377,000	4,988,000
Inventories	4,664,000	3,905,000
Prepaid expenses and other current assets	565,000	795,000
Total current assets	10,722,000	10,307,000
Equipment and leasehold improvements, net	2,309,000	3,415,000
Goodwill	4,579,000	4,579,000
Intangibles and patents, net	3,094,000	3,686,000
Other assets	151,000	229,000
Total Assets	20,855,000	22,216,000
Current liabilities:	'	'
Accounts payable	2,627,000	1,829,000
Accrued compensation	991,000	729,000
Accrued subcontracting costs	357,000	427,000
Other accrued expenses	1,067,000	871,000
Current portion of long-term debt, PFG, net discount of $262,000 and $0, respectively	1,642,000	714,000
Current portion of long-term debt - MEDC/MSF	654,000	553,000
Current portion of capital lease	8,000	'
Current portion of long-term debt - bank line of credit	1,128,000	'
Current portion of long-term debt - bank term loan	417,000	333,000
Total current liabilities	8,891,000	5,456,000
Long-term debt, less current portion - PFG, net discount of $0 and $405,000, respectively	'	1,322,000
Long-term debt, less current portion - MEDC/MSF	'	377,000
Long-term debt, capital lease	37,000	'
Long-term debt, less current portion - bank term loan	'	334,000
Warrant liability	505,000	292,000
Total liabilities	9,433,000	7,781,000
Commitments and contingencies	'	'
Shareholders' equity:	'	'
Class A Common Stock, $.001 par value, 100,000,000 authorized; December 27, 2013 - 31,240,740 shares issued and outstanding, March 31, 2013 - 31,158,347 shares issued and outstanding	31,000	31,000
Additional paid-in capital	58,724,000	58,616,000
Accumulated deficit	-47,333,000	-44,212,000
Total shareholders' equity	11,422,000	14,435,000
Total Liabilities and Shareholders' Equity	$20,855,000	$22,216,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 27, 2013	Mar. 31, 2013
Current portion of long-term debt, PFG, net discount	$262,000	$0
Long-term debt, less current portion - PFG, net discount	$0	$405,000
Class A Common Stock, par value	$0.00	$0.00
Class A Common Stock, authorized	100,000,000	100,000,000
Class A Common Stock, shares issued	31,240,740	31,158,347
Class A Common Stock, shares outstanding	31,240,740	31,158,347

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Dec. 27, 2013	Dec. 28, 2012	Dec. 27, 2013	Dec. 28, 2012
Sales, net	$7,450,000	$5,834,000	$22,064,000	$17,636,000
Cost of products sold	5,562,000	3,381,000	14,460,000	10,965,000
Gross profit	1,888,000	2,453,000	7,604,000	6,671,000
Operating expenses:	'	'	'	'
Research, development and engineering	1,164,000	1,558,000	3,890,000	4,271,000
Sales and marketing	640,000	527,000	1,867,000	1,528,000
General and administrative	1,135,000	1,087,000	3,461,000	3,259,000
Amortization expense	260,000	293,000	769,000	876,000
Total operating expenses	3,199,000	3,465,000	9,987,000	9,934,000
Loss from operations	-1,311,000	-1,012,000	-2,383,000	-3,263,000
Other income (expense):	'	'	'	'
Interest income	1,000	7,000	1,000	7,000
Interest expense	-154,000	-34,000	-479,000	-97,000
Change in fair value of warrant liability	-124,000	13,000	-213,000	26,000
Other income (loss)	-30,000	'	-47,000	22,000
Total other expense	-307,000	-14,000	-738,000	-42,000
Loss before benefit for income taxes	-1,618,000	-1,026,000	-3,121,000	-3,305,000
Benefit for income taxes	'	'	'	'
Net loss	($1,618,000)	($1,026,000)	($3,121,000)	($3,305,000)
Basic & diluted loss per share	($0.05)	($0.03)	($0.10)	($0.11)
Weighted average common shares outstanding	'	'	'	'
Basic & diluted	31,243,000	31,161,000	31,223,000	31,161,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Dec. 27, 2013	Dec. 28, 2012
Cash flows from operating activities:	'	'
Net loss	($3,121,000)	($3,305,000)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Depreciation	1,297,000	583,000
Amortization of intangible assets	769,000	876,000
Amortization of debt discount	143,000	'
Stock based compensation expense	110,000	124,000
Change in fair value of warrant liability	213,000	-26,000
Changes in operating assets and liabilities:	'	'
Accounts receivable - net	-389,000	769,000
Inventories	-759,000	-108,000
Prepaid expenses and other assets	291,000	-212,000
Accounts payable and accrued expenses	1,186,000	170,000
Net cash used in operating activities	-260,000	-1,129,000
Cash flows from investing activities:	'	'
Capital expenditures	-109,000	-316,000
Patent expenditures	-176,000	-98,000
Net cash used in investing activities	-285,000	-414,000
Cash flows from financing activities:	'	'
Payments on bank term loan	-250,000	-250,000
Net proceeds (payments) on bank line of credit	1,128,000	-500,000
Payments on MEDC/MSF term loans	-276,000	-397,000
Payments on PFG term loan	-537,000	'
Payments on capital lease	-21,000	'
Taxes paid on net share settlement	-3,000	'
Proceeds from exercise of stock options	1,000	'
Net cash provided (used in) by financing activities	42,000	-1,147,000
Net decrease in cash and cash equivalents	-503,000	-2,690,000
Cash and cash equivalents at beginning of period	619,000	3,249,000
Cash and cash equivalents at end of period	116,000	559,000
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	283,000	81,000
Supplemental disclosure of non-cash investing and financing activities:	'	'
Acquisition of equipment through capital lease	$82,000	'

Basis_of_Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Dec. 27, 2013
Basis of Presentation	'
	Note 1. Basis of Presentation

	Business Description

	General – Advanced Photonix, Inc. ® (the Company, we, us, our, or API), was incorporated under the laws of the State of Delaware in June 1988. API is a leading test and measurement company that packages optoelectronic semiconductors into high-speed optical receivers (HSOR products), custom optoelectronic subsystems (Optosolutions products) and Terahertz (THz products) instrumentation, serving a variety of global markets. The Company supports the customers from the initial concept and design phase of the product, through testing to full-scale production. The Company has three manufacturing facilities located in Camarillo, California, Ann Arbor, Michigan and Montreal, Canada.

	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and the Company’s wholly owned subsidiaries (Silicon Sensors Inc. Picometrix®, LLC, and Advanced Photonix Canada, Inc.). The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All material inter-company accounts and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the periods presented have been included. Operating results for the nine-month period ended December 27, 2013 are not necessarily indicative of the results that may be expected for the balance of the fiscal year ending March 31, 2014.

	These unaudited condensed consolidated financial statements should be read in conjunction with Management’s Discussion and Analysis and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2013, filed with the SEC on July 1, 2013.

Stock_Based_Compensation

Stock Based Compensation	9 Months Ended
Stock Based Compensation	Dec. 27, 2013
Stock Based Compensation	'
	Note 2. Stock Based Compensation

	The Company has three stock equity plans: The 1997 Employee Stock Option Plan, the 2000 Stock Option Plan and the 2007 Equity Incentive Plan. As of December 27, 2013, no additional awards may be issued under either the 1997 Employee Stock Option Plan or the 2000 Stock Option Plan. There are 2,500,000 shares authorized for issuance under the 2007 Equity Incentive Plan, with 197,095 shares remaining available for future grant.

	Options and restricted stock awards may be granted to employees, officers, directors and consultants. Options typically vest over a period of one to four years and are exercisable up to ten years from the date of issuance. The option exercise price equals the stock’s market price on the date of grant. Restricted stock awards typically vest over a period of six months to four years, and the shares subject to such awards are generally not transferrable until the awards vest.


	The following table summarizes information regarding options outstanding and options exercisable at each of the quarterly periods through the nine months ended December 28, 2012 and December 27, 2013, respectively, and the changes during the periods then ended:
			Number of				Weighted			Number of			Weighted
			Options				Average			Shares			Average
			Outstanding				Exercise Price			Exercisable			Exercise Price
			(000’s)				per Share			(000’s)			per Share
	Balance as of March 31, 2012			2,267			$	1.75			1,994		$	1.88
	Granted			125			$	0.63
	Exercised			(5	)		$	0.44
	Expired or forfeited			(5	)		$	0.44
	Balance as of June 29, 2012			2,382			$	1.69			2,023		$	1.86
	Granted			67			$	0.62
	Exercised			--			$	0
	Expired or forfeited			(11	)		$	2.26
	Balance as of September 28, 2012			2,438			$	1.66			2,058		$	1.83
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(31	)		$	1.19
	Balance as of December 28, 2012			2,407			$	1.67			2,085		$	1.81

			Number of				Weighted			Number of			Weighted
			Options				Average			Shares			Average
			Outstanding				Exercise Price			Exercisable			Exercise Price
			(000’s)				per Share			(000’s)			per Share
	Balance as of March 31, 2013			2,392			$	1.66			2,142		$	1.76
	Granted			24			$	0.48
	Exercised			--			$	--
	Expired or forfeited			(114	)		$	1.03
	Balance as of June 28, 2013			2,302			$	1.68			2,099		$	1.76
	Granted			--			$	--
	Exercised			(4	)		$	0.44
	Expired or forfeited			(19	)		$	1.8
	Balance as of September 27, 2013			2,279			$	1.68			2,117		$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(12	)		$	0.63
	Balance as of December 27, 2013			2,267			$	1.69			2,112		$	1.75
	Vested & expected to Vest, December 27, 2013			2,224			$	1.7

	Information regarding stock options outstanding as of December 27, 2013 is as follows:

				Options Outstanding
	Price Range			Shares (in				Weighted		Weighted Average
				000s)				Average		Remaining Life
								Exercise Price
	$0.44 - $1.25				537			$ 0.70		7.66
	$1.26 - $2.50				1,440			$ 1.82		3.31
	$2.51 - $5.34				290			$ 2.84		1.45

				Options Exercisable
	Price Range			Shares (in				Weighted		Weighted Average
				000s)				Average		Remaining Life
								Exercise Price
	$0.44 - $1.25				382			$ 0.70		7.48
	$1.26 - $2.50				1,440			$ 1.82		3.31
	$2.51 - $5.34				290			$ 2.84		1.45

The intrinsic value of options exercised during each of the three and nine month periods ended December 27, 2013 was zero and $600, respectively. The intrinsic value of options exercised during the three and nine month periods ended December 28, 2012 was zero and $1,100, respectively.

During the third quarter of fiscal 2013, no restricted shares were issued. There were no restricted shares issued during the third quarter of fiscal 2014. The restricted share transactions are summarized below:

		Shares (000’s)				Weighted Average Grant Date
		Shares (000’s)				Fair Value Per Share
Unvested, March 31, 2012			246			$	0.84
Granted			--			$	--
Vested			--			$	--
Expired or forfeited			--			$	--
Unvested, June 29, 2012			246			$	0.84
Granted			--			$	--
Vested			(76	)		$	0.82
Expired or forfeited			--			$	--
Unvested, September 28, 2012			170			$	0.84
Granted			--			$	--
Vested			--			$	--
Expired or forfeited			--			$	--
Unvested, December 28, 2012			170			$	0.84

		Shares (000’s)				Weighted Average Grant Date
		Shares (000’s)				Fair Value Per Share
Unvested, March 31, 2013			128			$	0.87
Granted			40			$	0.48
Vested			--			$	--
Expired or forfeited			(1	)		$	0.76
Unvested, June 28, 2013			167			$	0.78
Granted			50			$	0.66
Vested			(26	)		$	0.89
Expired or forfeited			(7	)		$	0.95
Unvested, September 27, 2013			184			$	0.72
Granted			--			$	--
Vested			(12	)		$	0.48
Expired or forfeited			(4	)		$	0.76
Unvested, December 27, 2013			168			$	0.74

The Company estimates the fair value of stock-based awards utilizing the Black-Scholes pricing model for stock options and using the intrinsic value for restricted stock. The fair value of the awards is amortized as compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The Black-Scholes fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. The factors include:

	1.	The time period that option awards are expected to remain outstanding has been determined based on the average of the original award period and the remaining vesting period. The expected term assumption for awards issued during the nine month periods ended December 27, 2013 and December 28, 2012 was 6.3 years.
	2.	The future volatility of the Company’s stock has been estimated based on the weekly stock price during the expected term to the date of the latest stock option grant. The expected volatility assumption for awards issued during the nine month periods ended December 27, 2013 and December 28, 2012 averaged 68% and 67%, respectively.
	3.	A dividend yield of zero has been assumed for awards issued during nine month periods ended December 27, 2013 and December 28, 2012, based on the Company’s actual past experience and the fact that Company does not anticipate paying a dividend on its shares in the near future.
	4.	The Company has based its risk-free interest rate assumption for awards issued during the nine month periods ended December 27, 2013 and December 28, 2012 on the implied yield available on U.S. Treasury issues with an equivalent expected term, which averaged 1.1% and 0.8% during each of the respective periods.
	5.	The forfeiture rate, for awards issued during the nine month periods ended December 27, 2013 and December 28, 2012, was 23% and 17%, respectively, and was based on the Company’s actual historical forfeiture history.

The Company’s stock-based compensation expense is classified in the table below:

		Three months ended							Nine months ended
		December 27,				December 28,			December 27,			December 28,
		2013				2012			2013			2012
Cost of Products Sold		$	1,000			$	3,000		$	5,000		$	10,000
Research, development & engineering expense			4,000				12,000			16,000			35,000
General and Administrative expense			31,000				28,000			70,000			69,000
Sales and Marketing expense			4,000				3,000			19,000			10,000
Total Stock Based Compensation		$	40,000			$	46,000		$	110,000		$	124,000

At December 27, 2013, the total stock-based compensation expense related to unvested stock options and restricted shares granted to employees and independent directors under the Company’s stock option plans but not yet recognized was $117,000. This expense will be amortized on a straight-line basis over a weighted-average period of approximately 1.2 years and will be adjusted for subsequent changes in estimated forfeitures.

Credit_Risk

Credit Risk	9 Months Ended
Credit Risk	Dec. 27, 2013
Credit Risk	'
	Note 3. Credit Risk

	Pervasiveness of Estimates and Risk - The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash equivalents and trade accounts receivable.

	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. API has never experienced any losses related to these balances. At December 27, 2013, there was no cash held in excess of federally insured limits.

	Accounts receivable are unsecured and the Company is at risk to the extent such amounts become uncollectible. The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. Any unanticipated change in the customers’ credit worthiness or other matters affecting the collectability of amounts due from such customers could have a material effect on the results of operations in the period in which such changes or events occur. As of December 27, 2013 two customers comprised 25% of accounts receivable. As of March 31, 2013, one customer individually comprised 12% of accounts receivable. The allowance for doubtful account balance was $23,000 on December 27, 2013 and $56,000 on March 31, 2013.

Detail_of_Certain_Asset_Accoun

Detail of Certain Asset Accounts	9 Months Ended
Detail of Certain Asset Accounts	Dec. 27, 2013
Detail of Certain Asset Accounts	'
	Note 4. Detail of Certain Asset Accounts

	Cash and Cash Equivalents - The Company considers all highly liquid investments, with an original maturity of three months or less when purchased, to be cash equivalents.

	Inventories - Inventories, which include material, labor and manufacturing overhead, are stated at the lower of cost (on a first in, first out method) or market. Inventories consist of the following at December 27, 2013 and March 31, 2013:

		27-Dec-13			31-Mar-13
	Raw material	$	3,117,000		$	2,600,000
	Work-in-process		932,000			782,000
	Finished products		615,000			523,000
	Inventories, net	$	4,664,000		$	3,905,000

	Slow moving and obsolete inventories are reviewed throughout the year to assess whether a cost adjustment is required. Our review of slow moving and obsolete inventory begins with a listing of all inventory items which have not moved regularly within the past 12 months. In addition, any residual inventory, which is customer specific and remaining on hand at the time of contract completion, is included in the list. The complete list of slow moving and obsolete inventory is then reviewed by the production, engineering and/or purchasing departments to identify items that can be utilized in the near future. These items are then excluded from the analysis and the remaining amount of slow-moving and obsolete inventory is then further assessed and a write down is recorded when warranted. Additionally, non-cancelable open purchase orders for parts we are obligated to purchase where demand has been reduced may also be reserved. Impairments for open purchase orders where the market price is lower than the purchase order price are also recorded. The impairments established for excess, slow moving, and obsolete inventory create a new cost basis for those items. The cost basis of these parts is not subsequently increased if the circumstances which led to the impairment change in the future. If a product that had previously been impaired is subsequently sold, the amount of reduced cost basis is reflected as cost of goods sold.

	Intangible Assets - Intangible assets that have definite lives consist of the following (dollars in thousands):

				27-Dec-13
		Weighted			Carrying		Accumulated		Intangibles
		Average		Amortization	Value		Amortization		Net
		Lives in		Method
		Years
	Customer list	15		Straight Line	$	190	$	109	$	81
	Trademarks	15		Cash Flow		2,270		1,227		1,043
	Technology	10		Cash Flow		10,950		10,491		459
	Distribution Rights	7		Straight Line		148		18		130
	Patents pending					717		--		717
	Patents	10		Straight Line		1,078		414		664
	Total Intangibles				$	15,353	$	12,259	$	3,094

				31-Mar-13
		Weighted			Carrying		Accumulated		Intangibles
		Average		Amortization	Value		Amortization		Net
		Lives in		Method
		Years
	Customer list	15		Straight Line	$	190	$	100	$	90
	Trademarks	15		Cash Flow		2,270		1,105		1,165
	Technology	10		Cash Flow		10,950		9,946		1,004
	Distribution Rights	7		Straight Line		148		2		146
	Patents pending					672		--		672
	Patents	10		Straight Line		946		337		609
	Total Intangibles				$	15,176	$	11,490	$	3,686

	Amortization expense for the three-month periods ended December 27, 2013 and December 28, 2012 was $260,000 and $293,000, respectively. The current patents held by the Company have remaining useful lives ranging from 2 years to 20 years. Amortization expense for the nine-month periods ended December 27, 2013 and December 28, 2012 was $769,000 and $876,000, respectively.

	The cash flow method of amortization is based upon management’s estimate of how the intangible asset contributes to our cash flows and best represents the pattern of how the economic benefits of the intangible asset will be consumed or used up. Such amortization is initially derived from the estimated undiscounted cash flows that were used in determining the original fair value of the intangible asset at the acquisition date and is monitored for significant changes in subsequent periods.

	Assuming no impairment to the intangible value, future amortization expense for intangible assets and patents, excluding patents pending, are as follows by fiscal year (in thousands):

	Intangible Assets and Patents
	Remainder of 2014	$	260
	2015		450
	2016		467
	2017		317
	2018		317
	2019 & after		566
	Total	$	2,377

	Patent pending costs of $717,000 are not included in the future amortization chart above. These costs will be amortized beginning the month the patents are granted.

Debt

Debt	9 Months Ended
	Dec. 27, 2013
Debt	'
	Note 5. Debt

	Total outstanding debt of the Company as of December 27, 2013 and March 31, 2013 consisted of the following (in thousands):
		27-Dec-13		31-Mar-13
	Bank term loan	$	417	$	667
	Bank line of credit		1,128		--
	MEDC/MSF loans		654		930
	Partners for Growth (PFG) loan, net of debt discount		1,642		2,036
	Capital leases		45		--
	Total	$	3,886	$	3,633

	Bank Debt
	On January 31, 2012, the Company entered into a loan and security agreement (and such other documents which constitute the SVB Loan Agreement) with Silicon Valley Bank (SVB). Subsequent to the initial SVB Loan Agreement, there have been four amendments that have modified the covenants, allowed for the acquisition of substantially all of the operating assets of Silonex, Inc. (Silonex), allowed for the grant to Partners for Growth III, L.P. (PFG) of a subordinated security interest in the Company’s collateral and extended the maturity date of the line of credit to March 31, 2014. The terms of the SVB Loan Agreement, as amended, provide for a $5.0 million line of credit with a $3.0 million Export-Import (EX-IM) sublimit at an interest rate that ranges from prime plus 50 basis points on up to prime plus 400 basis points depending on a liquidity ratio and adjusted three month rolling EBITDA as defined in the SVB Loan Agreement. The SVB Loan Agreement, as amended, contains a covenant for a minimum rolling three month adjusted EBITDA, measured monthly, and a minimum liquidity ratio of 2.25 to 1.00. The current adjusted EBITDA covenant allows for a negative adjusted EBITDA of $750,000 for each month during the period from January to June 2013, negative adjusted EBITDA of $300,000 for each month during the period July through October 2013, adjusted EBITDA of $1 for each month during the period November 2013 through February 2014, and adjusted EBITDA of $100,000 thereafter, subject to reset based on mutual agreement once a fiscal year 2015 budget is submitted to the lenders. The amount that can be drawn on the line of credit is subject to a formula based on our outstanding receivables and inventory. In addition, the SVB Loan Agreement, as amended, provided for a $1.0 million term loan with principal payable over three years in equal monthly installments and interest at a rate ranging from prime plus 100 basis points to prime plus 450 basis points dependent on the Company’s liquidity ratio and adjusted three month rolling EBITDA as defined in the SVB Loan Agreement. Under the SVB Loan Agreement, the Company may prepay all, but not less than all, of the term loan by paying a prepayment premium equal to (i) 1.00% of the amount outstanding if prepayment occurs before the first anniversary of the term loan; (ii) 0.50% of the amount outstanding if prepayment occurs after the first, but before the second anniversary of the term loan; and (iii) 0.25% of the amount outstanding if prepayment occurs after the second anniversary of the term loan. In addition, if the term loan becomes due and payable because of the occurrence and continuance of an Event of Default (as defined in the SVB Loan Agreement), API will be required to pay a termination fee equal to 1.00% of the amount outstanding. The interest rates on the SVB term loan and line of credit as of December 27, 2013 were 6.0% and 5.5%, respectively. The Company had $1,128,000 outstanding on the SVB line of credit with approximately $2.3 million in additional borrowing capacity as of December 27, 2013 prior to liquidity covenant restrictions. The EX-IM line of credit with SVB is guaranteed by the Company and its subsidiaries and all borrowings under the SVB Loan Agreement are secured by a first priority security interest granted to SVB over substantially all of the Company’s respective assets.

	As of December 27, 2013, the Company was not in compliance with the adjusted EBITDA covenant of $1 for the three months ended December 27, 2013. This constitutes an event of default under the terms of our credit facility agreement which gave SVB the ability to proceed against the collateral provided under the provisions of the SVB Loan Agreement. In addition and as described in greater detail below, unless the Company reaches an agreement with SVB to extend the term of the SVB line of credit, the outstanding balances under the SVB line of credit will become due and payable on March 31, 2014.

	On February 10, 2014, the Company and SVB entered into a forbearance agreement under which SVB agreed not to proceed against the collateral through February 28, 2014 and raised the interest rate on the line of credit and existing term debt to 7.25% and 7.75% effective February 1, 2014. This waiver did not amend or alter in any respect the terms and conditions of the agreement or any of the other loan documents, or constitute a waiver or release by SVB of any right, remedy or event of default under the agreement or any of the other loan documents, except to the extent expressly set forth in the forbearance agreement and the SVB loan agreement. The Company believes the forbearance agreement will allow time for the parties to agree upon new covenants and to negotiate an extension of the term of the SVB line of credit. There can be no assurance that the Company will be successful in negotiating new covenants and, because the forbearance agreement does not waive the current event of default, the failure to negotiate new covenants will adversely affect the Company’s business, financial position and results of operations and prevent the Company from making additional borrowings under the SVB line of credit. Given that the Company has not agreed with SVB on either the renewal of the line of credit or new covenants, the outstanding principal with SVB has been fully classified as a current liability.

	As noted above, the outstanding balances under the SVB line of credit will become due and payable on March 31, 2014. There can be no assurance that the Company will be successful in negotiating an extension of the term of the SVB line of credit. If the term of the SVB line of credit is not extended beyond March 31, 2014, the Company may not have adequate resources available to pay off the outstanding balances thereunder, which as of January 31, 2014 totaled $2,240,000. In addition to constituting an event of default under the terms of the SVB Loan Agreement, the failure to pay off all outstanding balances under the SVB line of credit when due will also constitute an event of default under the PFG Loan Agreement (as defined below), which in turn will entitle PFG to proceed against the collateral provided under the provisions of the PFG Loan Agreement, subject to any rights that SVB may have in that same collateral.

	API anticipates that additional financing will be necessary to fund both the repayment of its existing indebtedness and the future growth of the business and is pursuing both strategic alternatives and financing options at this time. There can be no assurance that additional financing will be available or the terms on which it might be available. If adequate financing is not available, or is not available on favorable terms, the Company’s business, financial position and results of operations will be adversely affected.

	The SVB term loan expires in March 2015 and the line of credit expires on March 31, 2014 since on January 22, 2014, the parties mutually agreed to extend the line of credit expiration date.

	Total interest payments made to the Company’s bank lenders during the nine months ended December 27, 2013 and December 28, 2012 were $57,000 and $43,000, respectively. Total interest payments made to the Company’s bank lenders during the three months ended December 27, 2013 and December 28, 2012 were $21,000 and $13,000, respectively

	MEDC/MSF Loans
	The Michigan Economic Development Corporation (MEDC) entered into two unsecured loan agreements with the Company’s subsidiary Picometrix: one in fiscal 2005 (MEDC Loan 1) and one in fiscal 2006 (MEDC Loan 2) for a total initial principal amount of $2.2 million. Both loans have been modified as to the interest rate and principal repayment terms in prior years. MEDC Loan 2 was assigned to the Michigan Strategic Fund (MSF) on October 28, 2009 although the MEDC continues to provide administrative services for MSF in regards to the loan. Effective November 6, 2013 , the Company and the MEDC agreed to defer principal payments on their two loans until maturity of the debts in the third quarter of fiscal 2015 in exchange for an increase in the annual interest from 4% to 5% and a 15% default rate of interest. As of the end of the quarter, both loans have an interest rate of 5% and the maturity dates on MEDC Loan 1 and on MEDC Loan 2 are December 1, 2014 and November 1, 2014, respectively. Prior to the amendment, the Company was making a monthly payment of $22,533 and $25,758 for principal and interest on MEDC Loan 1 and MEDC Loan 2 through their respective maturity dates. Given the amendment, the Company pays approximately $2,728 per month in interest with the principal due at maturity.

	Interest payments made to the MEDC/MSF were $25,000 and $38,000 during the nine months ended December 27, 2013 and December 28, 2012, respectively. Interest payments made to the MEDC/MSF were $8,000 and $10,000 during the three months ended December 27, 2013 and December 28, 2012, respectively.

	Partners for Growth Secured Debt
	On February 8, 2013, the Company entered into a secured debt agreement with PFG that is subordinated to SVB’s senior secured position (the PFG Loan Agreement). In conjunction with this transaction, on February 8, 2013 API executed a second amendment to the SVB loan to allow PFG a subordinated position and to adjust the previous covenant levels. On February 14, 2013, pursuant to the terms of the PFG Loan Agreement, the Company received $2.5 million in cash and was obligated to make monthly principal and interest payments beginning in March 2013 for 42 months at an interest rate of 11.75%. Consistent with a second amendment to the SVB Loan Agreement, the PFG Loan Agreement provided for a minimum rolling three month adjusted EBITDA covenant, measured monthly, on a go forward basis and a minimum liquidity ratio of 2.25 to 1.00. The new adjusted EBITDA covenant begins at a negative adjusted EBITDA of $750,000 for each month during the period February to June 2013, negative adjusted EBITDA of $300,000 for each month during the period July through October 2013, adjusted EBITDA of $1 for each month during the period November 2013 through February 2014, and adjusted EBITDA of $100,000 thereafter, subject to reset based on mutual agreement once a fiscal year 2015 budget is submitted to the lenders.

	As of December 27, 2013, the Company was not in compliance with the adjusted EBITDA covenant of $1 for the three months ended December 27, 2013. This constitutes an event of default under the terms of the PFG Loan Agreement which gave PFG the ability to proceed against the collateral provided under the provisions of the PFG Loan Agreement, subject to any rights that SVB may have in that same collateral. On February 10, 2014, the Company and PFG entered into a forbearance agreement under which PFG agreed not to proceed against the collateral through February 28, 2014. This waiver did not amend or alter in any respect the terms and conditions of the agreement or any of the other loan documents, or constitute a waiver or release by PFG of any right, remedy or event of default under the agreement or any of the other loan documents, except to the extent expressly set forth in the forbearance agreement and the PFG Loan Agreement. The Company believes the forbearance agreement will allow time for the parties to agree upon new covenants.

	API anticipates that additional financing will be necessary to fund both the repayment of its existing indebtedness and the future growth of the business and is pursuing both strategic alternatives and financing options at this time. There can be no assurance that additional financing will be available or the terms on which it might be available. If adequate financing is not available, or is not available on favorable terms, the Company’s business, financial position and results of operations will be adversely affected.

	As part of the consideration for the loan, the Company granted PFG and certain of its affiliates warrants to purchase up to 1,195,000 shares of Class A Common Stock with 995,000 of the shares issuable at $0.50 per share, and the remaining 200,000 shares issuable at a $1.00 strike price. In the event that the Company achieves at least $32,600,000 in sales and $412,000 in EBITDA during the fiscal year ending March 31, 2014, the warrant agreements (the PFG Warrant Agreements) provide that an aggregate of 100,000 of the $0.50 warrants and an aggregate of 100,000 of the $1.00 warrants will be cancelled. The PFG Warrant Agreements also include a net exercise provision pursuant to which the warrant holders would receive the number of shares equal to (i) the product of (A) the number of warrants exercised multiplied by (B) the difference between (1) the fair market value of a share of Class A Common Stock (with fair value generally being equal to the highest closing price of our Class A Common Stock during the 45 consecutive trading days prior to the date of exercise) and (2) the strike price of the warrant, (ii) divided by the fair market value of a share of Class A Common Stock. In addition, in the event the Company is acquired, liquidates, conducts a public offering, or the warrants expire, each warrant holder will have the right to “put” its warrants to the Company in exchange for a per share cash payment that varies with the number of shares issuable under each warrant, but in the aggregate will not exceed $250,000. The Company determined the fair value of the warrant as of the issuance date to be $434,000. Pursuant to the accounting literature, a debt discount and a warrant liability were established as of the issuance date with the debt discount amortized over the life of the loan on an effective interest method. As of December 27, 2013 and March 31, 2013, there was $262,000 and $405,000 respectively, in remaining unamortized debt discount offset against the PFG long term debt principal. See Note 6 to the Condensed Consolidated Financial Statements for additional information on the PFG warrants.

	Interest payments made to PFG during the three and nine month periods ended December 27, 2013 were $60,000 and $198,000, respectively. No interest payments were made to PFG during the three and nine month periods ended December 28, 2012.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Dec. 27, 2013
Stockholders' Equity	'
	Note 6. Stockholders’ Equity

	Warrants
	At December 27, 2013 and March 31, 2013, the Company had the following warrants outstanding and exercisable which could be exchanged into shares of Class A Common Stock:

		Shares (000’s)			Exercise Price
	2010 Warrants		267		$	1.376
	PFG Warrants		995		$	0.5
	PFG Warrants		200		$	1
	Total		1,462

	On November 29, 2010, the Company issued 267,196 warrants to Robin Risser and Steve Williamson (the 2010 Warrants). Each 2010 Warrant is exercisable over a five year period for one share of the Company’s Class A Common Stock at an exercise price subject to adjustment, based on a formula in the warrant agreements, if Common Stock is issued in the future below $1.404. Future adjustments cannot reduce the exercise price below $1.17. Given the issuance of the PFG Warrants in February 2013, a price reset was triggered to the 2010 Warrants and the new exercise price became $1.376. As a result of the exercise price reset feature, the fair values of the warrants are recorded as a liability with changes in values flowing through the Consolidated Statements of Operations.

	As described in Note 5, during February 2013, the Company issued warrants to PFG to purchase 1,195,000 shares of the Company’s Class A Common Stock. The PFG warrants are exercisable over a five year period with 995,000 shares at a strike price of $0.50 per share and another 200,000 shares with a strike price of $1.00 per share. The PFG warrant agreement contains a provision allowing the warrants to be put back to the Company under certain circumstances. Given this feature, the fair values of the warrants are recorded as a liability with changes in values flowing through the Consolidated Statements of Operations.

	For the three and nine months ended December 27, 2013, the Company recorded expense of $124,000 and $213,000, respectively for the change in fair value of the warrant liability. For the three and nine months ended December 28, 2012, the Company recorded income of $13,000 and $26,000 respectively. The fair value of the warrant liability outstanding was approximately $505,000 and $292,000 as of December 27, 2013 and March 31, 2013, respectively.

	The fair value of the warrant liability was estimated using the Monte Carlo option pricing model using the following assumptions:

		27-Dec-13						28-Dec-12
		PFG Warrants			2010 Warrants			2010 Warrants
	Contractual term in years		4.1			1.9			2.9
	Volatility		66.7	%		71.1	%		63.3	%
	Expected dividend		--			--			--
	Risk-free interest rate		1.3	%		0.4	%		0.35	%

	Expected volatility is based primarily on historical volatility using the weekly stock price for the most recent period equivalent to the term of the warrants. A dividend yield of zero has been assumed based on the Company’s actual past experience and the fact that the Company does not anticipate paying a dividend on its shares in the future. The Company has based its risk-free interest on the implied yield available on U.S. Treasury issues with equivalent contractual term.

	When a warrant may have different share exercise assumptions such as those issued in February 2013 to PFG and affiliates, the Company weighs various values based on the estimated probability of each outcome as of the valuation date.

	The following chart represents the activity in the Company’s Level 3 warrants during the nine months ended December 27, 2013 and the year ended March 31, 2013.

		Nine months Ended			Year Ended
		27-Dec-13			31-Mar-13
	Level 3 Warrants, beginning of period	$	292,000		$	26,000
	Addition – PFG Warrants, initial fair value		--			434,000
	Change in fair value of warrant liability		213,000			(168,000	)
	Level 3 Warrants, end of period	$	505,000		$	292,000

	MEDC Put Option
	In May 2010, the Company entered into a debt conversion agreement with the MEDC whereby the MEDC converted the accrued and unpaid interest as of November 30, 2009 totaling $562,336 into 1,041,363 unregistered shares of our Class A Common Stock at a price per share of $0.54 (market value of the stock on the day of conversion). In addition, the Company granted MEDC a put option to sell back the shares received pursuant to the debt conversion agreement in the event of a trigger event as defined in the debt conversion agreement. Given the conditions under which the put may be exercised are in the control of the Company, a liability for the fair value has not been recorded.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
Earnings Per Share	Dec. 27, 2013
Earnings Per Share	'
	Note 7. Earnings Per Share

	The Company’s net earnings per share calculations are in accordance with FASB ASC 260-10. Accordingly, basic earnings (loss) per share are computed by dividing net earnings (loss) by the weighted average number of shares outstanding for each period. The calculation of loss per share is as follows:

		Three months ended
	Basic and Diluted	27-Dec-13			28-Dec-12
	Weighted Average Basic Shares Outstanding		31,243,000			31,161,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		31,243,000			31,161,000
	Net loss	$	(1,618,000	)	$	(1,026,000	)
	Basic and Diluted loss per share	$	(0.05	)	$	(0.03	)

		Nine months ended
	Basic and Diluted	27-Dec-13			28-Dec-12
	Weighted Average Basic Shares Outstanding		31,223,000			31,161,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		31,223,000			31,161,000
	Net loss	$	(3,121,000	)	$	(3,305,000	)
	Basic and Diluted loss per share	$	(0.10	)	$	(0.11	)

	The dilutive effect of stock options and warrants for each of the periods was not included in the calculation of diluted loss per share because to do so would have had an anti-dilutive effect as the Company had a net loss for the period. As of December 27, 2013, the number of anti-dilutive shares excluded from diluted earnings per share totaled approximately 3.6 million shares, which includes 1,462,000 anti-dilutive warrants.

Silonex_Net_Asset_Purchase

Silonex Net Asset Purchase	9 Months Ended
Silonex Net Asset Purchase	Dec. 27, 2013
Silonex Net Asset Purchase	'
	Note 8. Silonex Net Asset Purchase

	On March 1, 2013, the Company, through its Advanced Photonix Canada, Inc. subsidiary (APC), acquired substantially all the operating assets and assumed certain liabilities of Silonex, Inc.’s business for $900,000 in cash, which was primarily funded with the PFG proceeds. Silonex designed, manufactured and marketed optoelectronic devices and sensor solutions to various vertical markets, including Industrial Controls, Banking, Vending, Medical and Telecommunications. The products, customers and business operations are complimentary to, and have minimal overlap with, the Company’s Optosolutions product line, and broaden the Company’s supply channel due to Silonex’s existing relationships with Chinese manufacturers. The results of operations of APC have been included in the consolidated financial statements since the date of the acquisition. The functional currency of APC is the US dollar.

	Silonex was part of a privately owned company, and prepared financial statements with multiple charge out of costs, intercompany sales and royalty arrangements that do not reflect the actual operation of the business as acquired. Therefore the Company has considered it impractical to reconstruct a full Statement of Operations on a proforma basis for prior comparable periods. Given certain assumptions on China sales which were done on a royalty basis, the Company has been able to estimate the total sales for the comparable three and nine months of fiscal 2013 at approximately $867,000 and $2.6 million, respectively. APC sales included in the Company’s results for the three month and nine months of fiscal 2014 were $840,000 and $2.8 million, respectively. The APC results from operations included in the Company’s results for the three and nine months of fiscal 2014 were a net loss of $12,000 and a net profit of $52,000, respectively.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Dec. 27, 2013
Fair Value of Financial Instruments	'
	Note 9. Fair Value of Financial Instruments

	The carrying value of all financial instruments potentially subject to valuation risk (principally consisting of cash equivalents, accounts receivable, and accounts payable) approximates the fair value based upon the short-term nature of these instruments. In the case of MEDC/MSF, PFG, and bank debt, the carrying value approximates fair value based upon prevailing interest rates available to the Company for debt of similar nature and maturity.

Restructuring

Restructuring	9 Months Ended
Restructuring	Dec. 27, 2013
Restructuring	'
	Note 10. Restructuring

	During the year, the Company made the decision to begin outsourcing the manufacturing of silicon photodiodes that are used in the Optosolutions production line to lower cost areas that were using larger production wafers. This opportunity became apparent with the acquisition and integration of the net assets of Silonex and could achieve annual cost savings of $400,000 to $600,000 per year when fully implemented. To prepare for the transition, an inventory level was built up and the fabrication assets idled during the quarter ended December 27, 2013. API undertook a review of the alternative uses of the equipment and determined that an accelerated depreciation charge of approximately $608,000 was necessary in the quarter to state the net book value of the idled assets at amounts that could be obtained if the equipment was sold to independent third party buyers. Employees affected by the shutdown of this manufacturing activity were provided severance of approximately $59,000 of which $44,000 was accrued in the current quarter and $15,000 in the quarter ended September 27, 2013. The total restructuring costs of $652,000 and $667,000 are reflected in the cost of goods sold section of the Statement of Operations for the three months and nine months ended December 27, 2013.

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	9 Months Ended
Stock Based Compensation (Tables)	Dec. 27, 2013
Summarized Information Regarding Options Outstanding and Options Exercisable	'
	The following table summarizes information regarding options outstanding and options exercisable at each of the quarterly periods through the nine months ended December 28, 2012 and December 27, 2013, respectively, and the changes during the periods then ended:
		Number of			Weighted		Number of		Weighted
		Options			Average		Shares		Average
		Outstanding			Exercise Price		Exercisable		Exercise Price
		(000’s)			per Share		(000’s)		per Share
	Balance as of March 31, 2012		2,267		$	1.75		1,994	$	1.88
	Granted		125		$	0.63
	Exercised		(5	)	$	0.44
	Expired or forfeited		(5	)	$	0.44
	Balance as of June 29, 2012		2,382		$	1.69		2,023	$	1.86
	Granted		67		$	0.62
	Exercised		--		$	0
	Expired or forfeited		(11	)	$	2.26
	Balance as of September 28, 2012		2,438		$	1.66		2,058	$	1.83
	Granted		--		$	--
	Exercised		--		$	--
	Expired or forfeited		(31	)	$	1.19
	Balance as of December 28, 2012		2,407		$	1.67		2,085	$	1.81

		Number of			Weighted		Number of		Weighted
		Options			Average		Shares		Average
		Outstanding			Exercise Price		Exercisable		Exercise Price
		(000’s)			per Share		(000’s)		per Share
	Balance as of March 31, 2013		2,392		$	1.66		2,142	$	1.76
	Granted		24		$	0.48
	Exercised		--		$	--
	Expired or forfeited		(114	)	$	1.03
	Balance as of June 28, 2013		2,302		$	1.68		2,099	$	1.76
	Granted		--		$	--
	Exercised		(4	)	$	0.44
	Expired or forfeited		(19	)	$	1.8
	Balance as of September 27, 2013		2,279		$	1.68		2,117	$	1.75
	Granted		--		$	--
	Exercised		--		$	--
	Expired or forfeited		(12	)	$	0.63
	Balance as of December 27, 2013		2,267		$	1.69		2,112	$	1.75
	Vested & expected to Vest, December 27, 2013		2,224		$	1.7
Options Outstanding and Options Exercisable	'
	Information regarding stock options outstanding as of December 27, 2013 is as follows:

			Options Outstanding
	Price Range		Shares (in			Weighted	Weighted Average
			000s)			Average	Remaining Life
						Exercise Price
	$0.44 - $1.25			537		$ 0.70	7.66
	$1.26 - $2.50			1,440		$ 1.82	3.31
	$2.51 - $5.34			290		$ 2.84	1.45

			Options Exercisable
	Price Range		Shares (in			Weighted	Weighted Average
			000s)			Average	Remaining Life
						Exercise Price
	$0.44 - $1.25			382		$ 0.70	7.48
	$1.26 - $2.50			1,440		$ 1.82	3.31
	$2.51 - $5.34			290		$ 2.84	1.45
Restricted Share Transactions	'
	The restricted share transactions are summarized below:

		Shares (000’s)			Weighted Average Grant Date
		Shares (000’s)			Fair Value Per Share
	Unvested, March 31, 2012		246		$	0.84
	Granted		--		$	--
	Vested		--		$	--
	Expired or forfeited		--		$	--
	Unvested, June 29, 2012		246		$	0.84
	Granted		--		$	--
	Vested		(76	)	$	0.82
	Expired or forfeited		--		$	--
	Unvested, September 28, 2012		170		$	0.84
	Granted		--		$	--
	Vested		--		$	--
	Expired or forfeited		--		$	--
	Unvested, December 28, 2012		170		$	0.84

		Shares (000’s)			Weighted Average Grant Date
		Shares (000’s)			Fair Value Per Share
	Unvested, March 31, 2013		128		$	0.87
	Granted		40		$	0.48
	Vested		--		$	--
	Expired or forfeited		(1	)	$	0.76
	Unvested, June 28, 2013		167		$	0.78
	Granted		50		$	0.66
	Vested		(26	)	$	0.89
	Expired or forfeited		(7	)	$	0.95
	Unvested, September 27, 2013		184		$	0.72
	Granted		--		$	--
	Vested		(12	)	$	0.48
	Expired or forfeited		(4	)	$	0.76
	Unvested, December 27, 2013		168		$	0.74
Stock Based Compensation Expense	'
	The Company’s stock-based compensation expense is classified in the table below:

		Three months ended					Nine months ended
		December 27,			December 28,		December 27,		December 28,
		2013			2012		2013		2012
	Cost of Products Sold	$	1,000		$	3,000	$	5,000	$	10,000
	Research, development & engineering expense		4,000			12,000		16,000		35,000
	General and Administrative expense		31,000			28,000		70,000		69,000
	Sales and Marketing expense		4,000			3,000		19,000		10,000
	Total Stock Based Compensation	$	40,000		$	46,000	$	110,000	$	124,000

Detail_of_Certain_Asset_Accoun1

Detail of Certain Asset Accounts (Tables)	9 Months Ended
Detail of Certain Asset Accounts (Tables)	Dec. 27, 2013
Inventories	'
	Inventories consist of the following at December 27, 2013 and March 31, 2013:

		27-Dec-13			31-Mar-13
	Raw material	$	3,117,000		$	2,600,000
	Work-in-process		932,000			782,000
	Finished products		615,000			523,000
	Inventories, net	$	4,664,000		$	3,905,000
Intangible assets that have definite lives	'
	Intangible assets that have definite lives consist of the following (dollars in thousands):

				27-Dec-13
		Weighted			Carrying		Accumulated		Intangibles
		Average		Amortization	Value		Amortization		Net
		Lives in		Method
		Years
	Customer list	15		Straight Line	$	190	$	109	$	81
	Trademarks	15		Cash Flow		2,270		1,227		1,043
	Technology	10		Cash Flow		10,950		10,491		459
	Distribution Rights	7		Straight Line		148		18		130
	Patents pending					717		--		717
	Patents	10		Straight Line		1,078		414		664
	Total Intangibles				$	15,353	$	12,259	$	3,094

				31-Mar-13
		Weighted			Carrying		Accumulated		Intangibles
		Average		Amortization	Value		Amortization		Net
		Lives in		Method
		Years
	Customer list	15		Straight Line	$	190	$	100	$	90
	Trademarks	15		Cash Flow		2,270		1,105		1,165
	Technology	10		Cash Flow		10,950		9,946		1,004
	Distribution Rights	7		Straight Line		148		2		146
	Patents pending					672		--		672
	Patents	10		Straight Line		946		337		609
	Total Intangibles				$	15,176	$	11,490	$	3,686
Future Amortization Expenses for Intangible Assets and Patents Excluding Patents Pending	'
	Assuming no impairment to the intangible value, future amortization expense for intangible assets and patents, excluding patents pending, are as follows by fiscal year (in thousands):

	Intangible Assets and Patents
	Remainder of 2014	$	260
	2015		450
	2016		467
	2017		317
	2018		317
	2019 & after		566
	Total	$	2,377

Debt_Tables

Debt (Tables)	9 Months Ended
Debt (Tables)	Dec. 27, 2013
Total Outstanding Debt	'
	Total outstanding debt of the Company as of December 27, 2013 and March 31, 2013 consisted of the following (in thousands):
		27-Dec-13		31-Mar-13
	Bank term loan	$	417	$	667
	Bank line of credit		1,128		--
	MEDC/MSF loans		654		930
	Partners for Growth (PFG) loan, net of debt discount		1,642		2,036
	Capital leases		45		--
	Total	$	3,886	$	3,633

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Dec. 27, 2013
Warrants Outstanding and Exercisable	'
	At December 27, 2013 and March 31, 2013, the Company had the following warrants outstanding and exercisable which could be exchanged into shares of Class A Common Stock:

		Shares (000’s)			Exercise Price
	2010 Warrants		267		$	1.376
	PFG Warrants		995		$	0.5
	PFG Warrants		200		$	1
	Total		1,462
Assumptions Used to Estimate Fair Value of Warrants	'
	The fair value of the warrant liability was estimated using the Monte Carlo option pricing model using the following assumptions:

		27-Dec-13						28-Dec-12
		PFG Warrants			2010 Warrants			2010 Warrants
	Contractual term in years		4.1			1.9			2.9
	Volatility		66.7	%		71.1	%		63.3	%
	Expected dividend		--			--			--
	Risk-free interest rate		1.3	%		0.4	%		0.35	%
Activity in Level Three Warrants	'
	The following chart represents the activity in the Company’s Level 3 warrants during the nine months ended December 27, 2013 and the year ended March 31, 2013.

		Nine months Ended			Year Ended
		27-Dec-13			31-Mar-13
	Level 3 Warrants, beginning of period	$	292,000		$	26,000
	Addition – PFG Warrants, initial fair value		--			434,000
	Change in fair value of warrant liability		213,000			(168,000	)
	Level 3 Warrants, end of period	$	505,000		$	292,000

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
Earnings Per Share (Tables)	Dec. 27, 2013
Earnings Per Share	'
	The Company’s net earnings per share calculations are in accordance with FASB ASC 260-10. Accordingly, basic earnings (loss) per share are computed by dividing net earnings (loss) by the weighted average number of shares outstanding for each period. The calculation of loss per share is as follows:

		Three months ended
	Basic and Diluted	27-Dec-13			28-Dec-12
	Weighted Average Basic Shares Outstanding		31,243,000			31,161,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		31,243,000			31,161,000
	Net loss	$	(1,618,000	)	$	(1,026,000	)
	Basic and Diluted loss per share	$	(0.05	)	$	(0.03	)

		Nine months ended
	Basic and Diluted	27-Dec-13			28-Dec-12
	Weighted Average Basic Shares Outstanding		31,223,000			31,161,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		31,223,000			31,161,000
	Net loss	$	(3,121,000	)	$	(3,305,000	)
	Basic and Diluted loss per share	$	(0.10	)	$	(0.11	)

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail)	9 Months Ended
	Dec. 27, 2013
	Facility
Basis of Presentation [Line Items]	'
Number of manufacturing facilities	3

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Dec. 27, 2013	Dec. 28, 2012	Dec. 27, 2013	Dec. 28, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares authorized for issuance under the 2007 Equity Incentive Plan	2,500,000	'	2,500,000	'
Shares remaining available for future grant under the 2007 Equity Incentive Plan	197,095	'	197,095	'
Intrinsic value of options exercised	$0	$0	$600	$1,100
Restricted shares issued	0	0	'	'
Expected term assumption for awards issued	'	'	'6 years 3 months 18 days	'6 years 3 months 18 days
Expected volatility assumption for awards issued	'	'	68.00%	67.00%
Dividend yield assumed for awards issued	'	'	0	0
Risk-free interest rate assumption for awards issued	'	'	1.10%	0.80%
Forfeiture rate for awards issued	'	'	23.00%	17.00%
Total stock-based compensation expense related to unvested stock options and restricted shares granted but not yet recognized	$117,000	'	$117,000	'
Stock-based compensation expense amortization period	'	'	'1 year 2 months 12 days	'
Stock Options \| Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'1 year	'
Stock Options \| Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'4 years	'
Options exercisable period from date of issuance	'	'	'10 years	'
Restricted Stock \| Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'6 months	'
Restricted Stock \| Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'4 years	'

Summarized_Information_Regardi

Summarized Information Regarding Options Outstanding and Options Exercisable (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 27, 2013	Sep. 27, 2013	Jun. 28, 2013	Dec. 28, 2012	Sep. 28, 2012	Jun. 29, 2012	Mar. 31, 2013	Mar. 31, 2012
Number of Options Outstanding	'	'	'	'	'	'	'	'
Beginning Balance	2,279	2,302	2,392	2,438	2,382	2,267	'	'
Granted	'	'	24	'	67	125	'	'
Exercised	'	-4	'	'	'	-5	'	'
Expired or forfeited	-12	-19	-114	-31	-11	-5	'	'
Ending Balance	2,267	2,279	2,302	2,407	2,438	2,382	'	'
Vested & expected to Vest	2,224	'	'	'	'	'	'	'
Weighted Average Exercise Price per Share	'	'	'	'	'	'	'	'
Beginning Balance	$1.68	$1.68	$1.66	$1.66	$1.69	$1.75	'	'
Granted	'	'	$0.48	'	$0.62	$0.63	'	'
Exercised	'	$0.44	'	'	$0	$0.44	'	'
Expired or forfeited	$0.63	$1.80	$1.03	$1.19	$2.26	$0.44	'	'
Ending Balance	$1.69	$1.68	$1.68	$1.67	$1.66	$1.69	'	'
Vested & expected to Vest	$1.70	'	'	'	'	'	'	'
Number of Shares Exercisable	'	'	'	'	'	'	'	'
Number of Shares Exercisable	2,112	2,117	2,099	2,085	2,058	2,023	2,142	1,994
Weighted Average Exercise Price per Share	'	'	'	'	'	'	'	'
Weighted Average Exercise Price per Share	$1.75	$1.75	$1.76	$1.81	$1.83	$1.86	$1.76	$1.88

Options_Outstanding_and_Option

Options Outstanding and Options Exercisable (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 27, 2013
$0.44 - $1.25	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Price Range, Lower range	$0.44
Options Outstanding Price Range, Upper Range	$1.25
Options Outstanding, Shares	537
Options Outstanding, Weighted Average Exercise Price	$0.70
Options Outstanding, Weighted Average Remaining Life	'7 years 7 months 28 days
Options Exercisable Price Range, Lower Range	$0.44
Options Exercisable Price Range, Upper Range	$1.25
Options Exercisable, Shares	382
Options Exercisable, Weighted Average Exercise Price	$0.70
Options Exercisable, Weighted Average Remaining Life	'7 years 5 months 23 days
$1.26 - $2.50	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Price Range, Lower range	$1.26
Options Outstanding Price Range, Upper Range	$2.50
Options Outstanding, Shares	1,440
Options Outstanding, Weighted Average Exercise Price	$1.82
Options Outstanding, Weighted Average Remaining Life	'3 years 3 months 22 days
Options Exercisable Price Range, Lower Range	$1.26
Options Exercisable Price Range, Upper Range	$2.50
Options Exercisable, Shares	1,440
Options Exercisable, Weighted Average Exercise Price	$1.82
Options Exercisable, Weighted Average Remaining Life	'3 years 3 months 22 days
$2.56 - $5.34	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Price Range, Lower range	$2.51
Options Outstanding Price Range, Upper Range	$5.34
Options Outstanding, Shares	290
Options Outstanding, Weighted Average Exercise Price	$2.84
Options Outstanding, Weighted Average Remaining Life	'1 year 5 months 12 days
Options Exercisable Price Range, Lower Range	$2.51
Options Exercisable Price Range, Upper Range	$5.34
Options Exercisable, Shares	290
Options Exercisable, Weighted Average Exercise Price	$2.84
Options Exercisable, Weighted Average Remaining Life	'1 year 5 months 12 days

Restricted_Share_Transactions_

Restricted Share Transactions (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 27, 2013	Sep. 27, 2013	Jun. 28, 2013	Sep. 28, 2012	Dec. 28, 2012	Mar. 31, 2012
Unvested Shares	'	'	'	'	'	'
Beginning balance	184	167	128	246	170	246
Granted	'	50	40	'	'	'
Vested	-12	-26	'	-76	'	'
Expired or forfeited	-4	-7	-1	'	'	'
Ending balance	168	184	167	170	170	246
Weighted Average Grant Date Fair Value Per Share	'	'	'	'	'	'
Beginning balance	$0.72	$0.78	$0.87	$0.84	$0.84	$0.84
Granted	'	$0.66	$0.48	'	'	'
Vested	$0.48	$0.89	'	$0.82	'	'
Expired or forfeited	$0.76	$0.95	$0.76	'	'	'
Ending balance	$0.74	$0.72	$0.78	$0.84	$0.84	$0.84

Stock_Based_Compensation_Expen

Stock Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
Stock Based Compensation Expense (Detail) (USD $)	Dec. 27, 2013	Dec. 28, 2012	Dec. 27, 2013	Dec. 28, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	$40,000	$46,000	$110,000	$124,000
Cost of Products Sold	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	1,000	3,000	5,000	10,000
Research, Development, and Engineering Expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	4,000	12,000	16,000	35,000
General and Administrative expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	31,000	28,000	70,000	69,000
Sales and Marketing Expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock based compensation expense	$4,000	$3,000	$19,000	$10,000

Credit_Risk_Additional_Informa

Credit Risk - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended
	Dec. 27, 2013	Mar. 31, 2013
	Customer	Customer
Concentration Risk [Line Items]	'	'
Percentage of account receivable from single customer	25.00%	12.00%
Number of customers	2	1
Allowance for doubtful account receivables	$23,000	$56,000

Inventories_Detail

Inventories (Detail) (USD $)	Dec. 27, 2013	Mar. 31, 2013
Inventory [Line Items]	'	'
Raw material	$3,117,000	$2,600,000
Work-in-process	932,000	782,000
Finished products	615,000	523,000
Inventories, net	$4,664,000	$3,905,000

Intangible_Assets_that_Have_De

Intangible Assets that Have Definite Lives (Detail) (USD $)	9 Months Ended	12 Months Ended
Intangible Assets that Have Definite Lives (Detail) (USD $)	Dec. 27, 2013	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	$15,353,000	$15,176,000
Accumulated Amortization	12,259,000	11,490,000
Intangibles Net	3,094,000	3,686,000
Customer list	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Original Average Lives in Years	'15 years	'15 years
Amortization Method	'Straight Line	'Straight Line
Carrying Value	190,000	190,000
Accumulated Amortization	109,000	100,000
Intangibles Net	81,000	90,000
Trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Original Average Lives in Years	'15 years	'15 years
Amortization Method	'Cash Flow	'Cash Flow
Carrying Value	2,270,000	2,270,000
Accumulated Amortization	1,227,000	1,105,000
Intangibles Net	1,043,000	1,165,000
Technology	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Original Average Lives in Years	'10 years	'10 years
Amortization Method	'Cash Flow	'Cash Flow
Carrying Value	10,950,000	10,950,000
Accumulated Amortization	10,491,000	9,946,000
Intangibles Net	459,000	1,004,000
Distribution Rights	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Original Average Lives in Years	'7 years	'7 years
Amortization Method	'Straight Line	'Straight Line
Carrying Value	148,000	148,000
Accumulated Amortization	18,000	2,000
Intangibles Net	130,000	146,000
Patents pending	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	717,000	672,000
Intangibles Net	717,000	672,000
Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Original Average Lives in Years	'10 years	'10 years
Amortization Method	'Straight Line	'Straight Line
Carrying Value	1,078,000	946,000
Accumulated Amortization	414,000	337,000
Intangibles Net	$664,000	$609,000

Detail_of_Certain_Asset_Accoun2

Detail of Certain Asset Accounts - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended	12 Months Ended	3 Months Ended
	Dec. 27, 2013	Dec. 28, 2012	Dec. 27, 2013	Dec. 28, 2012	Mar. 31, 2013	Dec. 27, 2013	Mar. 31, 2013	Dec. 27, 2013	Dec. 27, 2013	Dec. 27, 2013	Mar. 31, 2013
						Patents	Patents	Patents	Patents	Patents pending	Patents pending
								Minimum	Maximum
Certain Asset Accounts [Line items]	'	'	'	'	'	'	'	'	'	'	'
Amortization expense	$260,000	$293,000	$769,000	$876,000	'	'	'	'	'	'	'
Remaining useful lives of patents	'	'	'	'	'	'10 years	'10 years	'2 years	'20 years	'	'
Patent pending costs	$15,353,000	'	$15,353,000	'	$15,176,000	$1,078,000	$946,000	'	'	$717,000	$672,000

Future_Amortization_Expenses_f

Future Amortization Expenses for Intangible Assets and Patents Excluding Patents Pending (Detail) (USD $)	Dec. 27, 2013
In Thousands, unless otherwise specified	Dec. 27, 2013
Finite-Lived Intangible Assets [Line Items]	'
Remainder of 2014	$260
2015	450
2016	467
2017	317
2018	317
2019 & after	566
Total	$2,377

Total_Outstanding_Debt_Detail

Total Outstanding Debt (Detail) (USD $)	Dec. 27, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified	Dec. 27, 2013	Mar. 31, 2013
Debt Instrument [Line Items]	'	'
Bank term loan	$417	$667
Bank line of credit	1,128	'
MEDC/MSF loans	654	930
Partners for Growth (PFG) loan, net of debt discount	1,642	2,036
Capital leases	45	'
Total	$3,886	$3,633

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

Dec. 27, 2013

Mar. 31, 2013

Dec. 27, 2013

Dec. 28, 2012

Dec. 27, 2013

Dec. 28, 2012

Feb. 14, 2013

Dec. 27, 2013

Dec. 28, 2012

Dec. 27, 2013

Dec. 28, 2012

Mar. 31, 2013

Feb. 14, 2013

Dec. 27, 2013

Jan. 31, 2012

Jan. 22, 2014

Jan. 31, 2014

Jan. 31, 2012

Feb. 10, 2014

Dec. 27, 2013

Jan. 31, 2012

Feb. 10, 2014

Jan. 31, 2012

Dec. 27, 2013

Dec. 28, 2012

Dec. 27, 2013

Dec. 28, 2012

Dec. 27, 2013

Bank Term Loan

Partners for Growth III, L.P.

Silicon Valley Loan Agreement

Michigan Economic Development Corporation Loan Agreement

Michigan Economic Development Corporation Loan Agreement One

Michigan Economic Development Corporation Loan Agreement Two

Exercise Price 1

Exercise Price 2

Maximum

Period One

Period Two

Period Three

Period Four

Period Five

Subsequent Event

Export Import Sublimit

Bank Term Loan

Period One

Period Two

Period Three

Period Four

Amended Loan Agreement

Prior to Amendment

Amended Loan Agreement

Prior to Amendment

Minimum

Maximum

Minimum

Maximum

Before First Anniversary of Term Loan

After First but Before Second Anniversary of Term Loan

After Second Anniversary of Term Loan

Subsequent Event

Forbearance Agreement

Debt Instrument [Line Items]

Line of Credit

$5,000,000

$3,000,000

Additional interest above prime rate

0.50%

4.00%

1.00%

4.50%

Adjusted EBITDA

-750,000

-300,000

100,000

412,000

-750,000

-300,000

100,000

Liquidity ratio

2.25

Bank term loan

417,000

667,000

1,000,000

Loan payment period

'3 years

Percentage of prepayment premium over amount outstanding

1.00%

0.50%

0.25%

Percentage of termination fee on amount outstanding

1.00%

Interest rate on loan

6.00%

Interest rate on line of credit

5.50%

Line of credit outstanding

2,240,000

1,128,000

Line of credit, additional borrowing capacity

2,300,000

Debt instrument, interest rate

11.75%

7.25%

7.75%

4.00%

5.00%

4.00%

5.00%

SVB term loan expiry

'2015-03

Line Of Credit Expiry Date

31-Mar-14

Interest payments during a period

21,000

13,000

57,000

43,000

60,000

198,000

8,000

10,000

25,000

38,000

2,728

Debt instrument maturity date

1-Dec-14

1-Nov-14

Effective date of loans restructuring

6-Nov-13

Unsecured Debt

654,000

930,000

2,200,000

Default rate of interest

15.00%

Monthly principal and interest payments

22,533

25,758

Aggregate principal amount

2,500,000

Payment of loan period

'42 months

Issuance of common stock for warrants

1,195,000

995,000

200,000

Warrants strike price

$0.50

Warrant canceled

100,000

Maximum aggregate amount that warrant holder has the right to exchange

250,000

Consecutive trading days prior to the date of exercise

'45 days

Loan agreement, revenue requirement

32,600,000

Debt discount

434,000

Remaining unamortized debt discount

$262,000

$405,000

Warrants_Outstanding_and_Exerc

Warrants Outstanding and Exercisable (Detail)	Dec. 27, 2013	Feb. 28, 2013	Feb. 28, 2013	Dec. 27, 2013	Dec. 27, 2013	Dec. 27, 2013
		Warrant 1	Warrant 2	2010 Warrants	Partners for Growth III, L.P.	Partners for Growth III, L.P.
					Warrant 1	Warrant 2
Class of Warrant or Right [Line Items]	'	'	'	'	'	'
Warrants outstanding and exercisable	1,462,000	'	'	267,000	995,000	200,000
Exercise Price	'	0.5	1	1.376	0.5	1

Stockholders_Equity_Additional

Stockholders Equity - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

Feb. 28, 2013

Dec. 27, 2013

Dec. 28, 2012

Dec. 27, 2013

Dec. 28, 2012

Mar. 31, 2013

Mar. 31, 2012

Feb. 28, 2013

31-May-10

Feb. 28, 2013

Nov. 29, 2010

Feb. 28, 2013

Partners for Growth III, L.P.

Michigan Economic Development Corporation Loan Agreement

2010 Warrants

Warrant 1

Warrant 2

Minimum

Stockholders Equity Note [Line Items]

Issuance of warrants to Robin Risser and Steve Williamson

267,196

Warrant exercisable period

'5 years

Exercise price of warrant

1.404

1.17

0.5

New exercise price of warrants

$1.38

Issuance of warrants for common stock

1,462,000

1,195,000

Warrant exercise period

'5 years

Warrants exercisable

995,000

200,000

Change in fair value of warrant liability

($124,000)

$13,000

($213,000)

$26,000

$168,000

Fair value of warrants

505,000

292,000

26,000

Fair value assumption, dividend yield

0.00%

Accrued and unpaid interest

$562,336

Conversion of accrued and unpaid interest into class A common stock

1,041,363

Common stock price per share

$0.54

Assumptions_Used_to_Estimate_F

Assumptions Used to Estimate Fair Value of Warrants (Detail)	9 Months Ended
	Dec. 27, 2013	Dec. 28, 2012
Fair Value, Option, Quantitative Disclosures [Line Items]	'	'
Expected dividend	0.00%	'
Warrant	'	'
Fair Value, Option, Quantitative Disclosures [Line Items]	'	'
Contractual term in years	'1 year 10 months 24 days	'2 years 10 months 24 days
Volatility	71.10%	63.30%
Expected dividend	'	'
Risk-free interest rate	0.40%	0.35%
Warrant \| Partners for Growth III, L.P.	'	'
Fair Value, Option, Quantitative Disclosures [Line Items]	'	'
Contractual term in years	'4 years 1 month 6 days	'
Volatility	66.70%	'
Expected dividend	'	'
Risk-free interest rate	1.30%	'

Activity_in_Level_Three_Warran

Activity in Level Three Warrants (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
Activity in Level Three Warrants (Detail) (USD $)	Dec. 27, 2013	Dec. 28, 2012	Dec. 27, 2013	Dec. 28, 2012	Mar. 31, 2013
Class of Warrant or Right [Line Items]	'	'	'	'	'
Level 3 Warrants, beginning of period	'	'	$292,000	$26,000	$26,000
Addition - PFG Warrants, initial fair value	'	'	'	'	434,000
Change in fair value of warrant liability	124,000	-13,000	213,000	-26,000	-168,000
Level 3 Warrants, end of period	$505,000	'	$505,000	'	$292,000

Calculation_of_Income_Loss_Per

Calculation of Income Loss Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
Calculation of Income Loss Per Share (Detail) (USD $)	Dec. 27, 2013	Dec. 28, 2012	Dec. 27, 2013	Dec. 28, 2012
Basic and Diluted	'	'	'	'
Weighted Average Basic Shares Outstanding	31,243,000	31,161,000	31,223,000	31,161,000
Dilutive effect of Stock Options and Warrants	'	'	'	'
Weighted Average Diluted Shares Outstanding	31,243,000	31,161,000	31,223,000	31,161,000
Net loss	($1,618,000)	($1,026,000)	($3,121,000)	($3,305,000)
Basic and Diluted loss per share	($0.05)	($0.03)	($0.10)	($0.11)

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	9 Months Ended
Earnings Per Share - Additional Information (Detail)	Dec. 27, 2013
Earnings Per Share Disclosure [Line Items]	'
Anti-dilutive shares excluded from diluted earnings per share	3,600,000
Warrant	'
Earnings Per Share Disclosure [Line Items]	'
Anti-dilutive shares excluded from diluted earnings per share	1,462,000

Silonex_Net_Asset_Purchase_Add

Silonex Net Asset Purchase - Additional Information (Detail) (Silonex, USD $)	3 Months Ended		6 Months Ended	9 Months Ended
	Dec. 27, 2013	Sep. 28, 2012	Sep. 28, 2012	Dec. 27, 2013	Mar. 01, 2013
Silonex	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Business acquisition, purchase price	'	'	'	'	$900,000
Estimated sales	'	867,000	2,600,000	'	'
Proforma results of operations	840,000	'	'	2,800,000	'
Net profit (loss) due to acquisition	($12,000)	'	'	$52,000	'

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (Silonex, Outsourcing the manufacturing of Silicon Photodiodes, USD $)	3 Months Ended		9 Months Ended
	Dec. 27, 2013	Sep. 27, 2013	Dec. 27, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'
Accelerated Depreciation on Idle Assets	'	'	$608,000
Employee severance	44,000	15,000	59,000
Restructuring Cost	652,000	'	667,000
Minimum	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Business Acquisition cost savings	'	'	400,000
Maximum	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Business Acquisition cost savings	'	'	$600,000